psalexa
logo

Benign Prostatic Hyperplasia Therapeutics Market

Global Benign Prostatic Hyperplasia Therapeutics Market - Epidemiology Analysis, Therapy, Development, Growth and Demand Forecast to 2023

Delivery : 24-72 Working Hours
Report Code: LS10897
Available Format:

Chapter 1. Research Background

1.1. Research Objectives

1.2. Market Definition

1.3. Research Scope

1.3.1. Market Segmentation by Drug

1.3.2. Market Segmentation by Mechanism of Action

1.3.3. Market Segmentation by Geography

1.3.4. Analysis Period

1.3.5. Market Data Reporting Unit

1.3.5.1. Value

1.4. Key Stakeholders

Chapter 2. Research Methodology

2.1. Secondary Research

2.2. Primary Research

2.2.1. Breakdown of Primary Research Respondents

2.2.1.1. By region

2.2.1.2. By industry participant

2.2.1.3. By company type

2.3. Market Size Estimation

2.4. Data Triangulation

2.5. Assumptions for the Study

Chapter 3. Executive Summary

Chapter 4. Global BPH Pipeline Analysis

4.1. Overview

4.1.1. Pipeline analysis by Phase

4.1.2. Pipeline analysis by Mechanism of Action

4.1.3. Pipeline analysis by Molecule Type

4.1.4. Pipeline analysis by Route of Administration

4.1.5. Pipeline analysis by Company

Chapter 5. Global BPH Therapeutics Pipeline Analysis by Phase (2017)

5.1. Filed stage

5.2. Phase III

5.3. Phase II

5.4. Phase I

5.5. Pre-Clinical

5.6. Discovery

Chapter 6. Clinical Trials Review

6.1. Clinical Trials by Region

6.2. Clinical Trials by Trial Status

Chapter 7. Competitive Landscape of BPH Therapeutics Pipeline

7.1. Key Players Benchmarking for BPH Therapeutics Pipeline

7.2. SWOT Analysis of BPH Therapeutics Pipeline

7.2.1. Strengths

7.2.2. Weaknesses

7.2.3. Opportunities

7.2.4. Threats

Chapter 8. Epidemiology Analysis

Chapter 9. Market Introduction

9.1. Product Profiles of Branded Drugs

9.2. Definition of Market Segments

9.2.1. By Drug

9.2.1.1. Branded drugs

9.2.1.2. Generics

9.2.2. By Mechanism of Action

9.2.2.1. Alpha 1 adrenergic receptor antagonists

9.2.2.2. Cholestenone 5-alpha reductase inhibitors

9.2.2.3. Type 5 cyclic nucleotide phosphodiesterase inhibitors

9.2.2.4. Others

9.2.3. By Region

9.2.3.1. U.S.

9.2.3.2. EU5

9.2.3.3. Japan

9.3. Market Dynamics

9.3.1. Trends

9.3.2. Drivers

9.3.2.1. Impact analysis of drivers on market forecast

9.3.3. Restraints

9.3.3.1. Impact analysis of restraints on market forecast

9.3.4. Opportunities

9.4. Porter’s Five Forces Analysis

Chapter 10. Global Market Size and Forecast

10.1. By Drug

10.2. By Mechanism of Action

10.3. By Region

Chapter 11. U.S. Market Size and Forecast

11.1. By Drug

11.2. By Mechanism of Action

Chapter 12. EU5 Market Size and Forecast

12.1. By Drug

12.2. By Mechanism of Action

12.3. By Country – Germany, U.K., France, Italy, Spain

Chapter 13. Japan Market Size and Forecast

13.1. By Drug

13.2. By Mechanism of Action

Chapter 14. Competitive Landscape of BPH Therapeutics Market

14.1. Competitive Analysis of Key Players

14.2. Global Strategic Developments of Key Players

Chapter 15. Company Profiles

15.1. Sanofi Aventis

15.1.1. Business Overview

15.1.2. Product and Service Offerings

15.1.3. Key Financial Summary

15.1.4. Strategic Growth Plans

15.2. GlaxoSmithKline plc

15.2.1. Business Overview

15.2.2. Product and Service Offerings

15.2.3. Key Financial Summary

15.2.4. Strategic Growth Plans

15.3. Merck & Co. Inc.

15.3.1. Business Overview

15.3.2. Product and Service Offerings

15.3.3. Key Financial Summary

15.3.4. Strategic Growth Plans

15.4. Pfizer Inc.

15.4.1. Business Overview

15.4.2. Product and Service Offerings

15.4.3. Key Financial Summary

15.4.4. Strategic Growth Plans

15.5. Eli Lilly and Company

15.5.1. Business Overview

15.5.2. Product and Service Offerings

15.5.3. Key Financial Summary

15.5.4. Strategic Growth Plans

15.6. Astellas Pharma Inc.

15.6.1. Business Overview

15.6.2. Product and Service Offerings

15.6.3. Key Financial Summary

15.6.4. Strategic Growth Plans

15.7. Allergan, Inc.

15.7.1. Business Overview

15.7.2. Product and Service Offerings

15.7.3. Key Financial Summary

15.7.4. Strategic Growth Plans

15.8. Nymox Pharmaceutical Corporation

15.8.1. Business Overview

15.8.2. Product and Service Offerings

15.8.3. Key Financial Summary

15.8.4. Strategic Growth Plans

15.9. Jeil Pharmaceutical Co., Ltd.

15.9.1. Business Overview

15.9.2. Product and Service Offerings

15.9.3. Key Financial Summary

15.9.4. Strategic Growth Plans

15.10. Health Ever Bio-Tech Co., Ltd.

15.10.1. Business Overview

15.10.2. Product and Service Offerings

15.10.3. Key Financial Summary

15.10.4. Strategic Growth Plans

*Note: Key financial summary and strategic growth plans will be provided on best effort basis and is subject to availability of information during primary and secondary research.

Chapter 16. Appendix

16.1. Abbreviations

Place An Order

Single User License
question-mark

The report will be delivered in PDF format without printing rights. It is recommended for a single user.

USD 5100
Group License
question-mark

The report will be delivered in PDF format along with the printing rights. It is recommended for up to five users.

USD 6100
Enterprise License
question-mark

The report will be delivered in PDF format along with printing rights and detailed Excel sheet. It is recommended for organizations where multiple people would like to access the report from multiple locations.

USD 9100

Pre-Purchase Enquiry